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Abstract  
This review aims to discuss the different genetic 
alterations that may come about and thus give rise to 
thyroid cancer. The importance of understanding the 
pathogenesis of this disease is in the use of these genetic 
alterations as prognostic markers and as targets in 
treatment. Principal alterations to these central 
pathways, namely the MAPK pathway and PI3K/AKT 
pathway, are mutations, increase in gene number, 
methylations and translocations. The effects of the 
environment on the progression of thyroid cancer, such 
as the effects of the microenvironment and exposure to 
endocrine disruptors, will also be discussed. 
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Introduction  
While the prevalence of most cancers has remained 
the same or decreased, the incidence of thyroid cancer 
has increased.1 Therefore there is a great need for us to 
understand the mechanism of this disease since this may 
help us understand and determine the factors that are 
causing this increase in incidence. More importantly we 
hope that by understanding the pathogenesis of thyroid 
cancer we will be one step closer in finding a cure or at 
least a better treatment for this disease. The majority of 
thyroid cancers are derived from follicular cells, namely 
papillary carcinomas (PTC), follicular carcinomas (FTC), 
anaplastic carcinomas (ATC) and poorly differentiated 
thyroid cancers (PDTC). The remaining of thyroid 
cancers arise form parafollicular cells (also known as C 
cells) and are known as medullary thyroid cancers 
(MTC).2   
 
Mutations 
A mutation is a permanent change in the DNA 
sequence of a gene, this may be somatic or germline. A 
somatic mutation is one that occurs in somatic tissue i.e. 
any of the cells body except germ cell and so cannot be 
passed on to future generations. Germline muations 
occur in germ cells and so can be passed on to future 
generations. Two of the most common genetic mutations 
in thyroid cancer are those of BRAF and RAS, both of 
which are somatic mutations. BRAF is a gene coding for 
a proto-oncogene, the mutant form being BRAF-V600E.  
This form of mutation tends to be common and is 
commonly associated with papillary thyroid cancer. 
BRAF mutations have been shown to be related with 
poor clinicopathological outcomes and have a high risk 
of recurrence. It is also associated with metastasis of the 
lymph nodes, advanced stages of cancer and 
extrathyroidal extensions. BRAF-V600E leads to the 
continuous activation of the serine/threonine kinase, also 
known as the MAP kinase pathway (MAPK).  BRAF 
mutations are associated with an aggressive form of 
PTC, this is not seen in other mutations such as that of 
RAS (both of which are involved in the constitutive 
activation of MAPK pathway). This may come about as 
a result of the increased production of tumour promoting 
molecules such as vascular endothelial growth factor 
(VEGF), matrix metalloprotein, proinhibitin, Ki-67 and 
c-MET. BRAF-V600E is also associated with the 
methylation of the promoters of several tumour 
suppressor genes and therefore the decreased expression 
of the tumour suppressor genes. Both of these events 
make PTC particularly aggressive.3  
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RAS mutation is another very common mutation in 
thyroid cancer, following BRAF, but tends to be less 
aggressive.2 RAS proteins are GTPase proto-oncogenes, 
that are important in the regulation of the MAPK and 
PI3K/AKT pathways.4 The RAS mutation is associated 
with the transformation of follicular thyroid adenoma, 
which is a premalignant lesion, in thyroid cancer.2  PTCs 
with the RAS mutation tend to be encapsulated and have 
a lower rate of lymph node metastasis. 4 
 
Methylation  
Methylation is the addition of a methyl group to 
DNA. Hypomethylated genes are found to be over 
expressed in the presence of the BRAFV600E mutation. 
The hypo- or hyper-methylation of genes arises from 
signals that come about from the MAPK pathway driven 
by a mutation.5 The hypermethylation of promoters 
seems to be commonly associated with thyroid cancers 
and is the most common mechanism for the inactivation 
of genes. In fact methylation is also seen in the promoter 
of the PTEN gene, and is commonly seen in sporadic 
tumours. Normally PTEN acts as a tumour suppressor 
gene by down-regulating the PI3K/AKT pathway. The 
driving force of thyroid cancer from low grade to high 
grade is associated with the deviation of the PI3K/AKT 
pathway from its normal course. Thus a normally 
functioning PTEN gene prevents apoptosis. PTEN 
methylation results in the amplification and mutation of 
PIK3CA and is also associated with RAS mutations. This 
is commonly seen in FTC.6  
 
Translocations 
In translocation a segment from one chromosome 
breaks off and reattaches to a nonhomolgous 
chromosome or to a new site on the same chromosome. 
Chromosomal rearrangements involved in PTC are those 
of the proto-oncogenes RET and Neurotropic tyrosine 
kinase (NTRK1). DNA is susceptible to strand breaks 
when exposed to ionising radiation, something that is 
commonly seen in PTC. In fact there is a relationship 
between radiations, RET/PTC rearrangements leading to 
PTC formation.7 Chromosomal rearrangements come 
about not only because the gene loci involved have been 
damaged by radiation but also because they come in 
close vicinity during interphase of a thyroid cell.  
RET and NTRK1 rearrangements come about 
because of paracentric inversions. These events happen 
on chromosome 10 in the case of RET and on 
chromosome 1 in the case of NTRK1.8  Both of these 
proto-oncogenes code for tyrosine kinase receptors that 
are found on cell membranes. RET acts as a receptor for 
the growth factor of glial cell line-derived neurotrophic 
factor (GDNF) family, it permits the survival of many 
neurones and prevents apoptosis. NTRK1 binds nerve 
growth factor and is also important for the maintenance 
of neurons. RET and NTRK1 are both normally 
expressed in follicular C cells. eventually activate other 
cellular pathways including RAS/MAPK and PI3K. 
Chromosomal recombination retains the promoter and 
this results in the constitutive expression of the 
oncogene. The break point occurs between the coding 
sequence for the extracellular and transmembrane 
domain and that of the tyrosine kinase domain. 
Spontaneous dimerization comes about because of an 
intact protein-protein interaction domain. This results in 
ligand-independent autophosphorylation and therefore 
activation of downstream signalling cascades via cellular 
pathways. PTC can develop due to the chromosomal 
rearrangement of RET, unaided by other genetic 
alterations.7 The relationship of radiation in thyroid 
cancer was studied closely in post-Chernobyl patients. It 
was very clear that children exposed to radiation were 
more likely to develop functional PTC, and were found 
to have RET/PTC rearrangements, amongst other 
genetic alterations such as mutations leading to BRAF-
V600E.4 
 
Increases in gene number 
In thyroid cancers we also have an increase in 
genomic number, particularly those of the RTK genes 
and also of genes that code for members of the PI3K-
AKT pathway. These were even more evident in ATC, 
with the gain of the PDGFRα, PDGFRß, EGFR and 
VEGFR1 genes. The copy gain of RTK genes may act as 
potential therapeutic targets. The increase of the RTK 
gene more commonly interacts with AKT, that is, it 
promotes tumourigenesis and invasiveness though the 
PI3K/AKt pathway in ACT. 
Commonly increases in gene number are not seen 
as an isolated genetic alteration, but rather are seen to 
exist with mutations, as seen in ATC. This may aid in 
the irregular signalling of pathways. Genetic mutations 
are commonly associated with increases of the RTK 
genes. An exception to this is seen in FTC were PI3KCa 
increases in number, rather than RTK.9  
IQGAP1 (Ras GTPase-activating-like protein 1) is 
a scaffold protein. The increase expression of its 
corresponding gene plays a vital role in the spread of 
thyroid cancer. It may also be used as a marker and 
therapeutic target. The IQGAP1 polypeptide is very 
similar to the RAS- related GTP-ase proteins. In most 
cancer cells it might also be able to alter the RAS -> 
RAF -> MEK -> MAP kinase pathway.10 
 
MAPK signalling pathway  
An extracellular mitogen binds to a membrane 
bound receptor, this activates SOS which promotes the 
removal of GDP from RAS in exchange for GTP. This 
in turn activates RAF (MAP3K), which activates 
MAPK2, which then activates MAPK, which then 
activates transcription factors. Ras activates RAF which 
then phosphorylates and activates  MEK, thus 
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phosphorylating and activating MAPK. 11 
Mutant RTKs are a common genetic event in most 
forms of hereditary MTC. RET is a proto-oncogene, its 
activation leads to the constitutive activation of the 
MAPK pathway and this stimulates tumourigenesis. This 
hereditary mutant RET gene is commonly seen in 
patients with multiple endocrine neoplasia type 2A or 
2B or familial MTC.12 Constitutively active mutant RAF 
proteins that are typically seen in tumour cells, induce 
quiescent cultured cells to divide uncontrollably (even in 
the absence of hormones). On the other hand a 
constitutively active RAS protein cannot stimulate a 
defective RAF protein to proliferate.13 The most 
common mutations found in DTC are those of the BRAF 
gene. Most of the time a valine takes the place of a 
glutamine acid. The BRAF V600E mutation is 
associated with lymph node metastasis, extra thyroidal 
extension and advanced stage of the disease.12 The most 
common genetic alteration that occurs in sporadic adult 
papillary carcinomas is the BRAF point mutation. On the 
other hand patients who had been previously exposed to 
radiation, both accidentally and for therapeutic reasons, 
presented with a high frequency of RET/PTC 
rearrangements, with no or little occurrence of BRAF 
point mutations.1 
 
 
 
Figure 1: Diagram showing the events of the MAPK pathway. From Molecular Cell Biology. 7th edition. 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PI3K-AKT Pathway 
PTEN is one of the most commonly lost tumour 
suppressor genes, during tumour development mutations 
and deletions occur that inactivate its enzyme activity to 
increase cell proliferation and reduce cell death. PTEN is 
a natural inhibitor to the PI3K/AKT pathway. PTEN 
inhibits the conversion of PIP3 to PIP2.  PIP2 limits 
AKTs’ ability to bind to the membrane and therefore 
decrease activity. The increase in PIP3 results in an 
accumulation of AKT that is activated by PDK1. AKT 
activates mTOR by inhibiting TSC2, through 
phosphorylation. mTOR regulates protein translocation 
through phosphorylation of S6K1 and eIF4E binding 
proteins, this activates protein translation and cell 
survival. 15 
Increases in gene number of the PIK3Ca gene occur 
particularly in ATC and FTC, this leads to the over 
expression and activity of the PIK3Ca protein and thus 
phosphorylation of Akt. This is also associated with the 
conversion of precancerous epithelial lesions to cancer, 
distant metastasis and decreased patient survival.10 Thus 
RTK (receptor tyrosine kinase) uses the PI3K pathway 
to promote tumourigenesis and invasiveness of ATC and 
FTC. Then again this may be used to our advantage to 
target this genetic event as a potential therapeutic 
target.16 RAS is also involved in the PI3K pathway due 
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to RAS-binding site of p110 catalytic subunits such as 
that of PI3KCa. RAS mutations are associated with the 
phosphorylation of Akt. PTEN methylation is associated 
with genetic alterations in the PI3K-Akt pathway, such 
as hypermethylation of the PTEN gene which reduces 
the inhibitory effect of PTEN. PTEN methylation is in 
fact linked with aggressive cancer. 17 
 
Figure 2: Diagram showing the PI3K pathway. It depicts the different components of the PI3K-AKT and MAPK 
pathway that are typically affected in cancer. From Weigelt, B. & Downward, J. 2012. Genomic Determinants of PI3K 
Pathway Inhibitor Response in Cancer. Front Oncol.2012;2:109 
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The Role of BRAF-V600E in the microenvironment  
Patients with PTC who also have the BRAF-V600E 
mutation tend to exhibit a more aggressive clinical 
behaviour. This might be due to the effect of this 
mutation on the microenvironment thus effecting 
proliferation, motility, viability and adhesion. This 
mutation may also play a part in the conversion of PTC 
into ATC. Tumorignenesis is affected by the 
microenvironment of the tumour i.e. non-malignant 
cells. Genes that are abnormally expressed in cancer 
may code for receptors and proteins that have an effect 
on stromal cells such as endothelial cells, macrophages 
and smooth muscle cells, and on components of the 
extracellular matrix (ECM). Genes expressed by cells 
that harbour the BRAF-V600E mutation are for example 
those of the metallo-proteases (MMPs). MMPs are 
involved in the breakdown of the ECM and may 
therefore promote the tumour metastasis. The BRAF-
V600E mutation has also been shown to have an effect 
on thrombospondin-1 (TSP-1). In non-malignant cells, 
wild-type p53 inhibits angiogenesis by promoting the 
expression of TSP-1. Reduced expression of TSP-1 is 
associated with mutated RAS. The role of integrins is to 
attach the cell to the ECM. Some integrins may act as 
tumour suppressors and so there is a decreased 
expression as the cancer progresses, whereas other 
integrins promote tumour progression such as α2β1. 
ECM components may also interact together to promote 
cell proliferation, invasiveness and migration. For 
example, there seems to be a link between integrins and 
the N-terminal of TSP-1. Fibronectin is over expressed 
in BRAF-V600E positive cells. It promotes cancer 
invasiveness through its interaction with integrins. This 
is due to the constitutive signalling of BRAF-
V600E/ERK kinase. Targeting non-malignant 
components i.e. ECM molecules may provide a novel 
perspective to treating patients with such cancers.18  
 
Medullary Thyroid Cancer 
Medullary thyroid cancer is not as common and 
accounts for only 3-4% of thyroid cancers. Of these 75% 
are of the sporadic form while the other 25% account for 
hereditary cancers. Medullary thyroid cancer occurs in 
most cases of people who have the MEN 2a syndrome. 
This is associated with germline mutations in the RET 
(rearranged during transfection) proto-oncogene, in 
about 80% of patients this occurs in codon 634 on 
chromosome 10. Apart from medullary thyroid cancer, 
MEN 2a is also associated with phaeochromocytomas 
and parathyoird adenomas.19 
The primary oncogenic event is thought to be a 
mutation in the receptor tyrosine kinase. In fact therapies 
target this receptor leading to the development of 
tyrosine kinase inhibitors (TKI). A receptor tyrosine 
kinase that is coded for by the RET gene, binds to a 
family of ligands know as glial cell line-derived 
neurtrophic factor (GDNF). This in turn leads to the 
activation of two important pathways that are important 
in cell differentiation and cell growth, namely the 
RAS/mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3’ kinase (PI3K)/Akt. 
Another receptor that may be involved in MTC is 
also a tyrosine kinase receptor and is known as the 
epidermal growth factor receptor (EGFR). The binding 
of a ligand to this receptor leads to its dimerization and 
autophosphorylation, which then activates downstream 
signal pathways. This is involved in only a few MTCs, 
and was shown to be overexpressed, but not due to gene 
amplification but as result of polysomes. Therefore drug 
therapies may target EGFRs and such inhibitors do in 
fact inhibit the growth of MTC’s. 
On the other hand vascular endothelial growth 
factor receptors (VEGFR) are involved in angiogenesis. 
There are three main VEGFRs: VEGFR-1, VEGFR-2 
and VEGFR-3. VEGFR-2 is thought to be involved in 
tumour metastasis and growth. Tyrosine kinase 
inhibitors that block VEGFRs have been developed, 
however their effect is only short lived. Another receptor 
that may be overexpressed in MTC is the fibroblast 
growth factor receptor 4 (FGFR4). This receptor is 
usually involved in cell growth and proliferation and so 
inhibiting it would halt cell proliferation and therefore 
tumour growth. The tumour suppressor genes (TSG) 
retinoblastoma; pRB protein and p53 protein (TP53) are 
also involved in MTC’s. Their interaction with RET 
results in tumour growth. Mutations and therefore 
inactivation of both these genes are required in order to 
prevent apoptosis. Loss of another TSG may result in 
MTC, PTEN. This may lead to the constitutive 
activation of the PI3K/Akt pathway.20  
 
Conclusion  
The accumulation of genetic alterations of cellular 
pathways leads to their aberrant signaling. This is what 
then leads to the development and progression of cancer. 
These genetic alterations may function as markers and 
so have a vital role in diagnostics. On the other hand, 
knowledge of the cellular pathways is useful for 
therapeutic purposes. Knowledge of the effect of 
environmental factors may be useful for the prevention 
of cancer. For example we know that the formation of 
the RET/PTC oncogene is related to exposure of ionizing 
radiation. The link between endocrine disruptors and the 
development of cancer in children may further 
emphasize the importance of prenatal care.   
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